Skip to main content
69°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Johnson & Johnson
(NY:
JNJ
)
151.33
+1.72 (+1.15%)
Official Closing Price
Updated: 7:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Johnson & Johnson
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
99
100
Next >
Google Goes Nuclear For AI Power, Israeli Restraint Impacts Stocks, Gold, And Oil
October 15, 2024
To gain an edge, this is what you need to know today.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On Strong Cancer Drug Sales, Revises Annual Outlook To Reflect V-Wave Acquisition
October 15, 2024
Johnson & Johnson reported third-quarter earnings with adjusted EPS of $2.42, surpassing expectations. Sales rose 5.2% to $22.47B. J&J updated its 2024 adjusted EPS guidance, lowering it slightly to...
Via
Benzinga
Johnson & Johnson’s Medtech Segment Shines With Impressive Q3 Growth
October 15, 2024
Johnson & Johnson's third-quarter performance exceeded expectations, with adjusted EPS of $2.42 against an expected $2.19.
Via
Talk Markets
Johnson & Johnson Earnings Top; Dow Giant Works Toward Buy Point
October 15, 2024
J&J stock edged higher early Tuesday.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Why NYSE:JNJ is a Top Pick for Dividend Investors.
October 15, 2024
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics.
Via
Chartmill
This Is What Whales Are Betting On Johnson & Johnson
October 14, 2024
Via
Benzinga
Market Whales and Their Recent Bets on JNJ Options
October 11, 2024
Via
Benzinga
Wall Street On Edge As Nasdaq Nears Record High, Oil Prices Plummet: Strategist Says There's Opportunity If Resilience Continues
October 15, 2024
Wall Street mood has become circumspect as traders gear up to receive a slew of earnings reports this week amid the market’s record run. The Nasdaq Composite has been a laggard among the major averages...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
October 15, 2024
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson Reports Q3 2024 Results
October 15, 2024
From
Johnson & Johnson
Via
Business Wire
What Analysts Are Saying About Johnson & Johnson Stock
October 10, 2024
Via
Benzinga
3 Mega-Cap Stocks For Long-Term Dividend Growth
October 10, 2024
Mega cap stocks have the size and economies of scale to pay long-term dividends to shareholders.
Via
Talk Markets
Insights Into Johnson & Johnson's Performance Versus Peers In Pharmaceuticals Sector
October 10, 2024
Via
Benzinga
Jim Cramer Says Earnings Season Will Fuel Market's Record Run, But Warns Of This 'Horrendous' Headwind That Could Apply Brakes To Rally
October 15, 2024
The stock market has been on a two-year strong run and the extended rally has begun to stir valuation concerns.
Via
Benzinga
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
October 14, 2024
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana.
Via
Talk Markets
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
October 14, 2024
Via
Benzinga
More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug
October 14, 2024
On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of mirikizumab compared with a placebo and active control (Johnson & Johnson’s...
Via
Benzinga
Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals
October 14, 2024
JNJ's 3Q earnings expected to be $2.21 EPS and $22.16B revenue. Recent acquisitions and drug trials impacting stock's stagnant performance.
Via
Benzinga
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
October 14, 2024
Big pharmaceutical firms may lack the potential for rally driven by a breakout drug like small biotechs, but stability and steady growth remain attractive.
Via
MarketBeat
Columbus Day: Is Stock Market Open Today?
October 14, 2024
Investors should brace for a busy week with earnings reports from major companies.
Via
Benzinga
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
October 13, 2024
Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there.
Via
MarketBeat
All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year
October 13, 2024
Target, PepsiCo, and Kenvue have high yields and inexpensive valuations.
Via
The Motley Fool
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
October 12, 2024
Johnson & Johnson is a leader in the pharmaceutical, medical device, and consumer products industries. Here are some highlights from a quantitative analysis of the company's stock.
Via
Talk Markets
Stocks Extend Weekly Win Streaks To 5
October 11, 2024
Wall Street enjoyed healthy gains to close out both the day and week.
Via
Talk Markets
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
October 11, 2024
Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on...
Via
Benzinga
Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference
October 10, 2024
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson Completes Acquisition of V-Wave
October 09, 2024
From
Johnson & Johnson
Via
Business Wire
1 Vanguard Index Fund Could Turn $500 Per Month Into a $968,400 Portfolio That Pays $16,000 in Annual Dividend Income
October 09, 2024
Workers with median earnings can build sizable portfolios that pay hefty amounts of passive income in retirement.
Via
The Motley Fool
Should Investors Consider High Yield Dividend Stocks?
October 09, 2024
When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield. But are high-yield stocks always the best route for income-focused investors?...
Via
Talk Markets
What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week?
October 08, 2024
Johnson & Johnson discontinues the Phase 3 SunRISe-2 trial for TAR-200 in bladder cancer, citing lack of superiority. Q3 earnings forecasted to hit $22.26 billion with 4.4% growth, as the company eyes...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.